| Document |
Document Title |
|
WO/2008/092120A1 |
The present invention provides a novel class of macrocyclic compounds as well as complexes formed between a metal (e.g., lanthanide) ion and the compounds of the invention. Preferred complexes exhibit high stability as well as high quant...
|
|
WO/2008/087177A1 |
This invention relates to novel semicarbazide and carbonylhydrazide derivatives that are found to be potent modulators of potassium channels and, as such, they are valuable candidates for the treatment of diseases or disorders as diverse...
|
|
WO/2008/086733A1 |
The invention provides a new pharmaceutical composition for treating cardiovascular disease, which contains the active component 2-butyl-4-chlorine-1-[2'-(1H-tetrazol-5-yl)1.1'-biphenyl-met
hyl]imidazole-5-carboxylic acid,1-[(isopropoxy)...
|
|
WO/2008/083543A1 |
A nitrogen-containing heterocyclic modified compounds and their uses in preparing the medicaments of preventing and treating the Alzheimer's disease, Parkinson's disease and other degenerative nervous system disease or type two diabetes....
|
|
WO/2008/074756A1 |
The invention relates to novel biphenyl thio-urea derivatives of Formula (I), wherein A represents hydroxy or tetrazolyl; R1 represents halo, hydroxy or phenyl, which phenyl may optionally be substituted with halo; and R2 and R3, indepen...
|
|
WO/2008/072758A1 |
Disclosed is a metal complex represented by the formula (A-1) or (B-1) below. This metal complex is excellent in heat resistance and acid resistance, and useful for redox reaction catalysts and the like.
|
|
WO/2008/071400A1 |
The present invention relates to a new method for the production of valsartan, a valine derivative having the chemical name is (S)-N-(1 -carboxy-2-methylprop-1 -yl)-N-pentanoyl-N- [2'-(1 H-tetrazol-5-yl)-biphenyl-4-ylmethyl]amine, and ph...
|
|
WO/2008/072032A1 |
The novel positively charged pro-drugs of beta-lactam antibiotics in the general 'Structure 4' were designed. The positively charged amino group of the pro-drug not only makes the drugs soluble in water, but also bonds to the negative ch...
|
|
WO/2008/068516A1 |
A compound of the formula: wherein R1 is selected from H, methyl, ethyl, carboxyl protecting groups and hydrophilic moieties, R2 and R3 are independently selected from H, methyl, ethyl and carboxyl protecting groups, R4 is selected from ...
|
|
WO/2008/060399A2 |
In certain aspects, the present invention relates to metal coordinating complexes for use as imaging contrast agents. For instance, in some embodiments, the present invention is directed to an imaging contrast agent including a metal che...
|
|
WO/2008/056776A1 |
Disclosed are a tetrazolium mesoionic compound having low melting point, an ionic liquid using such a tetrazolium mesoionic compound, and a method for producing such a tetrazolium mesoionic compound. Specifically disclosed is a tetrazoli...
|
|
WO/2008/051017A1 |
The present invention relates to a cleavage agent and a cleavage method selectively acting on soluble assembly of amyloidogenic peptide or protein.
|
|
WO/2008/046463A1 |
The invention relates to the subject matters characterized in the claims, namely metal chelates having a perfluorinated PEG group, a method for the production thereof, and the use thereof, a method for the production thereof, and the use...
|
|
WO/2008/030618A1 |
The present invention provides compounds useful, for example, for treating metabolic disorders in a subject. Such compounds have the general formula I: where the definitions of the variables Q, L1, ℗, L2, M, X, L3, and A are provided h...
|
|
WO/2008/028937A1 |
A compound of formula (I) or a pharmaceutically acceptable salt or prodrug ester thereof: Formula (I) wherein the groups R1-R5, R10 and X1-X7 are as defined in the specification.
|
|
WO/2008/027385A2 |
Provided are processes for the synthesis of 5 -phenyl- 1-trityl-lH-tetrazole, an intermediate useful in the synthesis of irbesartan. The tritylation of 5-phenyl-lH-tetrazole is carried out using phase transfer catalysis in a biphasic sol...
|
|
WO/2008/026937A1 |
The invention relates to an improved method of dynamic nuclear polarisation (DNP) of carboxylic acids and to compounds and compositions for use in the method.
|
|
WO/2008/021804A2 |
Disclosed herein is a compound having a structure: Therapeutic methods, compositions, and medicaments relating thereto are also disclosed.
|
|
WO/2008/018843A1 |
The invention relates to processes for producing pharmaceutically useful salt form of biphenyl-tetrazole compounds of the following formula by replacement of the acidic tetrazole proton with alkali metal or replacement of the alkali meta...
|
|
WO/2008/012852A1 |
The present invention relates to novel substituted biphenyltetrazole compounds useful as intermediates in the preparation of angiotensin II antagonists, to a process for the synthesis of them and to a process for the conversion thereof t...
|
|
WO/2008/006875A1 |
The present invention relates to hydroximoyl-tetrazole derivatives of formula (I) wherein T represent a tetrazolyl substituents, A represents a carbo- or heterocycle, L1 and L2 represent various linking groups and Q represents a carbocyc...
|
|
WO/2008/007391A2 |
The present invention relates to an improved process for the preparation of valsartan compound of formula-1 through novel intermediate compounds. It also relates to a novel process for the preparation of amorphous form of valsartan.
|
|
WO/2008/006874A1 |
The present invention relates to hydroximoyl-tetrazole derivatives of formula (I) wherein T 5 represent a tetrazolyl substituent, A represents a carbo- or heterocycle, L1 and L2 represent various linking groups and Q represents a 6-membe...
|
|
WO/2008/004110A2 |
The present invention provides a method for the preparation of N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-y
l]methyl]-L-valine (Valsartan) which comprises; treating N-[[2'-(1-triphenylmethyl-tetrazol-5-yl)biphenyl-4-yl]me...
|
|
WO/2008/000645A1 |
Compounds of the formula (I) or a pharmaceutically acceptable salt thereof, wherein, R1 is optionally substituted tetrazolyl, R2 is optionally substituted phenyl, optionally substituted pyridinyl or optionally substituted thienyl, and R3...
|
|
WO/2007/144512A2 |
The invention relates to compounds of formula (I): in which: R1 is an alkanoyl group, R2 is an alkyl group substituted with a group G, or R1 and R2 form, together with the nitrogen atom which bears them, an imidazolyl or benzimidazolyl g...
|
|
WO/2007/134709A1 |
5-Iodotetrazoles of the formula (I) in which R1 has the meaning given in the description are exceptionally suitable for use as medicaments, in particular for the combating/prophylaxis of mycoses in humans and mammals.
|
|
WO/2007/132005A2 |
The invention relates to novel hybrid compounds comprising at least one polyol entity (Po) - for example oligomer or polymer - in which at least one of the hydroxyl functions of Po is substituted by at least one entity A that can be of a...
|
|
WO/2007/128874A1 |
This invention concerns novel labeling reactants based on azacycloalkanes, wherein a suitable group is linked to the molecule allowing introduction of the said molecules to bioactive molecules in solution or on solid phase.
|
|
WO/2007/128873A1 |
This invention relates to a new method for the preparation of chelating agents or metal chelates, particularly lanthanide(III) chelates, tethered to a maleimido function and to novel end products and intermediates produced in said method...
|
|
WO/2007/130890A2 |
Therapeutic substituted cyclopentane compounds, and compositions, medicaments, and therapeutic methods related thereto are disclosed herein.
|
|
WO/2007/125585A1 |
[PROBLEMS] To provide a method for producing a bitetrazolamine compound in good yield, with safety, and advantageously from a commercial view point. [MEANS FOR SOLVING PROBLEMS] A method for producing a bitetrazolamine compound represent...
|
|
WO/2007/123186A1 |
A TLR signaling inhibitor, preferably an inhibitor of the production of various cytokines such as IL-8 or an inflammatory mediator, an inhibitor of the expression of COX-II or the like or an inhibitor of various kinases such as ATF2 cont...
|
|
WO/2007/124351A1 |
The present invention relates to compounds having the general formula (I) with the definitions of X, Y, R1, R2, R3, R4, R9, R10 given below, and solvates, hydrates, esters, and pharmaceutically acceptable salts thereof. Furthermore the i...
|
|
WO/2007/119246A2 |
The present invention relates to an improved process for the manufacture of Losartan potassium. The process comprises of condensation of 2-butyl-4-chloro-5-formyl imidazole with 2-cyano-4-bromomethyl biphenyl in a biphasic solvent system...
|
|
WO/2007/113634A1 |
The present invention relates to novel compounds representated by formula (I), where R, R1, R2, R3, X, Y, m, n are as defined.The present invention relates to compounds of the general formula I their derivatives, their analogs, their tau...
|
|
WO/2007/106546A2 |
Improved methods for synthesizing bifunctional chelates of tetraazamacrocycle derivatives and intermediates thereof are disclosed as well as novel tetraazamacrocycle derivatives and intermediates thereof.
|
|
WO/2007/104135A1 |
A bifunctional polyazamacrocyclic chelating agent of the formula (I): wherein: and the variables A, L, Q, Q1, X, Y, Z, Z1, m, n and r are as defined in the description of the present application. Also described is a complex of the above ...
|
|
WO/2007/105049A1 |
Dibenzyl amine compounds and derivatives, of Formula (I), pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to l...
|
|
WO/2007/105050A1 |
Dibenzyl amine compounds and derivatives, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain oth...
|
|
WO/2007/103456A2 |
This invention relates to piperazine and piperidine biaryl compounds of Formula (I) or a pharmaceutically acceptable prodrug, salt, polymorph, solvate, enantiomer, diastereomer, racemate, mixture of stereoisomers thereof, or derivative t...
|
|
WO/2007/092364A2 |
The present invention encompasses compounds of Formula I: as well as pharmaceutically acceptable salts and hydrates thereof, that are useful for treating atherosclerosis, dyslipidemias and the like. Pharmaceutical compositions and method...
|
|
WO/2007/091616A1 |
A polynuclear metal complex having in each molecule not only at least one large cyclic ligand having 5 to 15 coordinating atoms but also multiple metal atoms is subjected to any of heating treatment, radiation exposure treatment and elec...
|
|
WO/2007/088558A2 |
The present invention relates to a process for purification of Valsartan comprising steps of: (i) crystallizing from an organic solvent (ii) washing the crystallized product obtained in step (i) with a solvent selected from a group consi...
|
|
WO/2007/085349A1 |
The novel process for iodinating substituted azoles, especially for iodinating substituted 1H-tetrazoles and substituted 1H-triazoles, affords the desired compounds in high purity and with good yield.
|
|
WO2007032019B1 |
The invention relates to novel compound of formula (IV), which is an organic acid salt of N-[(2'-cyanobiphenyl-4-yl)methyl]-(L)-valine ester. This compound is an useful intermediate for process of preparation of Valsartan of formula (I),...
|
|
WO/2007/083538A1 |
Disclosed is an epoxy bleedout-preventing agent which has no adverse effect on die bonding strength and assembly characteristics and does not deteriorate effects of coloration preventing treatment and sealing even when a low-stress die b...
|
|
WO/2007/074213A1 |
This invention concerns novel labeling reactants, which are derivatives of macrocyclic chelators and which allow site specific introduction of the ligand of said derivatives to oligonucleotides molecules on solid phase.
|
|
WO/2007/071750A1 |
It comprises a preparation process of Valsartan from new salts of Valsartan having the tetrazole moiety protected with a protective group. The process leads to the elimination of the typical impurities due to the preparation process whil...
|
|
WO/2007/069684A1 |
Disclosed is a phthalamide derivative represented by the general formula (I) or a salt thereof, which shows an excellent controlling effect for use as an agricultural or horticultural pesticide alone or in combination with other agricult...
|
